SCM
Soleus Capital Management Portfolio holdings
AUM
$1.45B
This Quarter Return
+7.62%
1 Year Return
+18.23%
3 Year Return
+274.85%
5 Year Return
+440.77%
10 Year Return
–
AUM
$993M
AUM Growth
+$993M
(+10%)
Cap. Flow
+$136M
Cap. Flow
% of AUM
13.75%
Top 10 Holdings %
Top 10 Hldgs %
39.81%
Holding
126
New
24
Increased
29
Reduced
26
Closed
35
Top Buys
| 1 |
GSK
GSK
|
$34.2M |
| 2 |
Treace Medical Concepts
TMCI
|
$25M |
| 3 |
TG Therapeutics
TGTX
|
$20.5M |
| 4 |
Insulet
PODD
|
$20.4M |
| 5 |
Teva Pharmaceuticals
TEVA
|
$18.4M |
Top Sells
| 1 |
Charles River Laboratories
CRL
|
$22.2M |
| 2 |
SGEN
Seagen Inc. Common Stock
SGEN
|
$13.7M |
| 3 |
Arcellx
ACLX
|
$12.9M |
| 4 |
CVS Health
CVS
|
$11.3M |
| 5 |
RETA
Reata Pharmaceuticals, Inc. Class A Common Stock
RETA
|
$9.95M |
Sector Composition
| 1 | Healthcare | 98.3% |
| 2 | Consumer Staples | 1.7% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
26
SI-BONE Inc
SIBN
$700M
| $13.6M | 1.26% |
642,289
+16,145
| +3% | +$343K |
|
|
27
CVS Health
CVS
$93B
| $13.4M | 1.24% |
192,554
-162,500
| -46% | -$11.3M |
|
28
AtriCure
ATRC
$1.73B
| $13.4M | 1.24% |
+306,000
| New | +$13.4M |
|
29
ESSA Pharma
EPIX
$11.2M
| $13.2M | 1.22% |
4,287,094
+85,000
| +2% | +$263K |
|
|
MREO
30
Mereo BioPharma
MREO
$275M
| $12.5M | 1.15% |
+9,677,419
| New | +$12.5M |
|
31
Bausch Health
BHC
$2.72B
| $11.6M | 1.07% |
1,408,801
+253,301
| +22% | +$2.08M |
|
32
Verastem
VSTM
$585M
| $11M | 1.01% |
1,347,369
+827,000
| +159% | +$6.72M |
|
33
BioNTech
BNTX
$24.1B
| $10.6M | 0.98% |
+98,000
| New | +$10.6M |
|
|
INBX
34
DELISTED
Inhibrx, Inc. Common Stock
INBX
| $10.1M | 0.93% |
549,183
+76,000
| +16% | +$1.39M |
|
|
RYZB
35
DELISTED
RayzeBio, Inc. Common Stock
RYZB
| $10M | 0.92% |
+451,163
| New | +$10M |
|
36
Soleno Therapeutics
SLNO
$3.56B
| $9.59M | 0.88% |
+325,000
| New | +$9.59M |
|
37
Merus
MRUS
$5.04B
| $9.07M | 0.84% |
+384,490
| New | +$9.07M |
|
|
BCYC
38
Bicycle Therapeutics
BCYC
$492M
| $7.87M | 0.73% |
391,800
-20,000
| -5% | -$402K |
|
39
BioAtla
BCAB
$28.7M
| $7.41M | 0.68% |
4,356,197
+35,000
| +0.8% | +$59.5K |
|
40
Pharvaris
PHVS
$1.41B
| $7.18M | 0.66% |
343,975
-47,925
| -12% | -$1M |
|
|
CMPS
41
Compass Pathways
CMPS
$452M
| $7.14M | 0.66% |
+964,550
| New | +$7.14M |
|
42
Nuvalent
NUVL
$5.74B
| $7.1M | 0.65% |
154,416
-58,584
| -28% | -$2.69M |
|
43
Inspire Medical Systems
INSP
$2.53B
| $7.06M | 0.65% |
35,600
+28,900
| +431% | +$5.73M |
|
44
Exact Sciences
EXAS
$9.33B
| $6.97M | 0.64% |
102,196
+32,696
| +47% | +$2.23M |
|
45
Nurix Therapeutics
NRIX
$723M
| $6.4M | 0.59% |
+814,000
| New | +$6.4M |
|
46
BioLife Solutions
BLFS
$1.2B
| $6.06M | 0.56% |
+439,000
| New | +$6.06M |
|
47
Jasper Therapeutics
JSPR
$44.2M
| $5.81M | 0.54% |
830,098
+52,500
| +7% | +$368K |
|
48
Iovance Biotherapeutics
IOVA
$800M
| $5.64M | 0.52% |
1,239,777
| – | – |
|
49
NovoCure
NVCR
$1.35B
| $5.56M | 0.51% |
344,100
+99,000
| +40% | +$1.6M |
|
50
Insmed
INSM
$30.3B
| $5.5M | 0.51% |
+218,000
| New | +$5.5M |
|